Side-by-side comparison of AI visibility scores, market position, and capabilities
Oracle Corporation's healthcare IT division (rebranded Cerner, $28.3B acquisition 2022); #2 US hospital EHR, VA/DoD federal EHR program, OCI cloud migration + ambient clinical AI competing with Epic Systems.
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, revenue cycle management, and population health analytics to hospitals, health systems, physician practices, ambulatory clinics, and government health agencies globally — operating as the rebranded Cerner Corporation following Oracle's $28.3 billion acquisition of Cerner in June 2022, the largest acquisition in Oracle's history. Oracle Health's EHR platform (the Cerner Millennium clinical information system) powers clinical documentation, physician order entry, nursing workflows, medication administration, and patient care coordination for approximately 30% of US hospitals — making Oracle Health the second-largest EHR vendor in the US hospital market after Epic Systems. A major integration program is underway to migrate Cerner's clinical applications to Oracle Cloud Infrastructure (OCI), enabling Oracle Health to leverage Oracle's cloud scale, Oracle's AI capabilities (generative AI for clinical documentation, ambient listening for physician notes), and Oracle's database performance advantages for health record analytics. Oracle Corporation named Clay Magouyrk and Mike Sicilia as co-CEOs in 2025 (replacing Safra Catz), positioning Oracle Health's clinical platform to benefit from the next-generation Oracle leadership team's emphasis on cloud and AI transformation.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.